News

News Archive

New CELLSEARCH<sup>®</sup> Circulating Multiple Myeloma Test now available to help community physicians optimize patient care

New CELLSEARCH® Circulating Multiple Myeloma Test now available to help community physicians optimize patient care

As the market leader in cell-based liquid biopsies, Menarini Silicon Biosystems is offering community hematology-oncologists an opportunity to have patient blood samples sent to a US...
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

Florence (Italy) November 4th, 2021 – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Go to Follow our blog

Follow our blog

Discover our stories from all over the world

Read More